{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-26-000096","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2026-08-06T20:03:19+00:00","discovered_at":"2026-08-06T20:04:01.419413+00:00","generated_at":"2026-08-06T20:04:08.689333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Denali Q2 net loss $127.6M; AVLAYAH revenue $3.6M; PRV sale adds $195M; DNL151 discontinued in idiopathic PD","bullets":["Q2 2026 net loss $127.6M vs $124.1M YoY; R&D $97.0M, SG&A $36.3M.","AVLAYAH (Hunter syndrome) first full quarter net revenue $3.6M; Q3 guidance $10-12M.","PRV sale closed July 2026 for $195M gross; pro forma cash >$1.1B.","DNL151 (Parkinson's) Phase 2b LUMA failed; development in idiopathic PD discontinued; BEACON study for LRRK2 carriers continues.","DNL593 (FTD-GRN) results delayed to 2027; Takeda terminated collaboration in April (strategic)."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-26-000096","json":"https://secwatch.observer/filing/0001714899-26-000096.json","markdown":"https://secwatch.observer/filing/0001714899-26-000096.md","text":"https://secwatch.observer/filing/0001714899-26-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/0001714899-26-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/dnli-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:04:08.689333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}